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USAAbstract
Background: Personal genome analysis is now being considered for evaluation of
disease risk in healthy individuals, utilizing both rare and common variants. Multiple
scores have been developed to predict the deleteriousness of amino acid substitutions,
using information on the allele frequencies, level of evolutionary conservation, and
averaged structural evidence. However, agreement among these scores is limited
and they likely over-estimate the fraction of the genome that is deleterious.
Method: This study proposes an integrative approach to identify a subset of
homozygous non-synonymous single nucleotide polymorphisms (nsSNPs). An 8-level
classification scheme is constructed from the presence/absence of deleterious predictions
combined with evidence of association with disease or complex traits. Detailed literature
searches and structural validations are then performed for a subset of homozygous 826
mis-sense mutations in 575 proteins found in the genomes of 12 healthy adults.
Results: Implementation of the Association-Adjusted Consensus Deleterious Scheme
(AACDS) classifies 11% of all predicted highly deleterious homozygous variants as most
likely to influence disease risk. The number of such variants per genome ranges from 0
to 8 with no significant difference between African and Caucasian Americans. Detailed
analysis of mutations affecting the APOE, MTMR2, THSB1, CHIA, αMyHC, and AMY2A
proteins shows how the protein structure is likely to be disrupted, even though the
associated phenotypes have not been documented in the corresponding individuals.
Conclusions: The classification system for homozygous nsSNPs provides an opportunity
to systematically rank nsSNPs based on suggestive evidence from annotations and
sequence-based predictions. The ranking scheme, in-depth literature searches, and
structural validations of highly prioritized mis-sense mutations compliment traditional
sequence-based approaches and should have particular utility for the development of
individualized health profiles. An online tool reporting the AACDS score for any variant
is provided at the authors’ website.
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Personal genome interpretation is a process of determining the personal genome sequences
and assessing the likely consequences of an individual’s genetic variation. Personalized
genome data interpretation can be used, for example, to predict diseases and traits,
identify mutations for family planning purposes, and guide medical treatments based
on likely drug responses. Developments in next-generation sequencing technologies
over the past five years have enabled personal genome interpretation to become feasible
and affordable [1]. Despite these advances, understanding of the impact of specific genetic
variants remains limited. Major efforts have been made to identify nsSNPs with
strong effects because of their collective high prevalence and likelihood that many
may be clinically actionable [2].
Sequence-based prediction algorithms are commonly used to categorize nsSNPs into
damaging and non-damaging, and to predict the effects (small or large) of nsSNPs with
respect to undesirable phenotypes. The algorithms score the amino acid changes from
the level of sequence conservation observed in homologous sequences or from the degree
of physicochemical changes. Structure-based predictions evaluate three-dimensional (3D)
structural features, e.g., solvent accessibility, stability, number of residue contacts, which
are altered in the mutant proteins. Approaches that include annotation of biological
function also support functional assessments of amino acid substitutions. Ng and
Henikoff (2006) proposed that the combination of all three types of data may provide the
most accurate assessment of likely deleteriousness [3], which motivates the development
of the schema proposed in this study.
A pioneer study in personal genome interpretation stated that the human reference
genome carries 1104 nsSNPs predicted to have impact on protein functions [4]. A similar
study indicated that there are 796–837 predicted deleterious nsSNPs per individual [5].
This number of predicted damaging nsSNPs is much greater than both the theoretically
estimated 15–60 damaging nsSNPs per genome [2] and the classified disease-causing
nsSNP number of 40–100 per genome [6]. These observations highlight the complexity of
personal genome interpretation and the need for a variant classification schema that
builds on algorithmic prediction by integrating sound knowledge of the biological and
structural impact of genetic variants.
There are many databases that provide useful information about genetic variants.
Because genetic polymorphisms found in healthy individuals tend to have small effects,
further improvement of available resources is required to more accurately define
the set of variants that are likely to be most important for an individual’s health.
In this study, we constructed a classification schema (Figure 1, Additional file 1:
Figure S1) to rank nsSNPs identified in healthy individuals by their functional
significance. Each ranking category reflects the strength of evidence that a variant
may adversely affect gene function from several standpoints, incorporating both
database searches and sequence-based predictions. The newly developed variant
classification scheme is designed to generate a best estimate of clinical significance
for each variant of interest, with the intention of focusing attention on the most likely
deleterious SNPs.
Given the very large number of candidate disease-promoting variants per genome, we
here focus just on the homozygous variants reasoning that highly penetrant effects are most
likely to be recessive. The methods developed could be applied to all heterozygous nsSNPs
Figure 1 Flow diagram for AACDS classification algorithm. Upon receiving a list of homozygous rare
mis-sense variants, the nsSNPs were mapped to the corresponding amino acid residue within a reference
protein (identified with UniProt accession number). We use an SQL server to hold SNP-related information
from several resources: deleterious predictions (from dbSNFP database [10]), known diseases associations of
each variant and known disease/trait associations of each gene (from MSV3d [14], SwissVar [15], and GWAS
databases [17]). The AACDS classification algorithm extracts relevant fields from the AACDS database to
populate the report on the variant category (categories 1–6). The output (Additional file 1: Figure S1) is
converted from an SQL data table to the user-defined formats (HTML, text), and is available for download,
or individual queries can be supported on our server at http://aacds.cig.biology.gatech.edu/?q=tools.
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ranted given extensive phenotype data and a desire of an individual to receive the informa-
tion. Here we describe homozygous nsSNPs in the genomes of 12 healthy participants in a
predictive health study, the Emory-Georgia Tech Center for Health Discovery and Well
Being (CHDWB). Since the IRB consent does not allow communication of genetic data,
given potential negative consequences of knowledge of variants that cannot be acted upon,
the identities of the individuals are anonymous and no concerted attempt has been made
here to link genotypes to phenotypes directly. Expanded and appropriately consented studies
will be required to evaluate the actual utility of the proposed schema as a means of focusing
attention on those variants that are most likely to influence personalized health behaviors.
Methods
Whole genome sequence dataset
Whole genome sequence (WGS) data was obtained for 12 healthy adult participants in
the Center for Health Discovery and Well Being (CHDWB) study, including 4 African
American women, 4 Caucasian women, and 4 Caucasian men. None of the individuals
has any known complex or Mendelian diseases, but they cover a variety of profiles with
respect to overall physical and mental health. Prediction of disease risk based on common
variants and clinical profiles is described for the Caucasians in [7]. The participants have
provided written consent to publication of their whole genome sequence data for research
purposes only. They do discuss their clinical profile with a health professional following
annual visits to the Center, but are not currently permitted to receive the genetic data
generated during the study. In order to protect participant identities, their identifying
numbers have been randomized for this study.
WGS was performed on Illumina HiSeq2000 automated sequencers at the University
of Washington facility under contract to the Illumina Genome Network. Approximately
125 billion bases passing the Illumina analysis filter were obtained for each genome.
Preeprem and Gibson BioData Mining 2013, 6:24 Page 4 of 23
http://www.biodatamining.org/content/6/1/24Mean non-N reference coverage (after excluding gaps) is ~36X with 95.5% of the positions
having an average coverage of at least 10X. The genome sequences were aligned against
the human reference genome assembly (hg19 sequence) using CASAVA (Consensus
Assessment of Sequence And VAriation, Illumina, Inc, San Diego, CA). On average, 87%
of each individual’s quality filtered reads were aligned. High-confidence variants with a
quality score above 20 were retained. Accuracy of the generated genome sequences
was confirmed by comparison with previously determined genotypes from Illumina
OmniQuad arrays, which showed >99% concordance for all individuals.
The coding variants were functionally annotated using Variant Annotation Tool (VAT)
[8] which uses the GENCODE v7 gene annotation set [9]. We identified “homozygous rare
variants” with allele frequency <10% in the Caucasian or African 1000 Genomes dataset,
using the data provided by dbNSFP [10]. All homozygous rare nsSNPs relative to hg19
were identified for each person, and assigned to two categories: known nsSNPs that are
present in dbSNP build 137 [11], and private nsSNPs that are absent from dbSNP but
found exclusively in each individual. Information on the number of variants of each type
is provided in Table 1. Minor allele frequencies (MAFs) for all nsSNPs were obtained from
NHLBI GO Exome Sequencing Project (ESP6500) (June 2012 release) [12]. Genomic data
for known homozygous nsSNPs (n = 826, including 29 private variants) were analyzed as a
whole and per individual.
Amino acid indices for the alternate residues were mapped to the corresponding proteins
using transcript IDs for the major isoform. All protein sequences and related information
including protein functions and sequence features were obtained from the UniProt
database [13].Sequence annotation using published algorithms
Evidence for association of each SNP or gene with diseases or traits was obtained from
public repositories of amino acid polymorphisms (MSV3d, July 2012 release [14] and
SwissVar, accessed December 2012) [15], from Online Mendelian Inheritance in Man
(OMIM) [16], and from the NHGRI genome wide association studies (GWAS) [17]
catalog. Initially, each nsSNP was assigned as disease-causing, probably disease causing,
unclassified, or neutral. Functional predictions, and information on disease- and trait-
associations to the gene were collected from dbNSFP [10]. In addition, we used UniProt
sequence feature records [13] to annotate whether the mutated amino acid is localized
to any structurally/functionally important sites (molecule processing sites, binding
sites, modification sites, etc.).
To annotate deleterious nsSNPs, consensus predictions from several algorithms were
compared. Pre-computed deleterious scores for each nsSNP were retrieved from dbNSFP
[10]. To our knowledge, dbNSFP is the first database that provides pre-computed
functional predictions from multiple algorithms, facilitating interpretation of the deleteri-
ousness of variants in large datasets. The database provides the output of six different
prediction algorithms that have complimentary methodologies. Three are sequence-
based (SIFT [18], LRT [5], and MutationAssessor [19]), while two are both sequence
and structure-based (PolyPhen2_HumDiv and PolyPhen2_HumVar [20]), and the
sixth is the MutationTaster Bayesian classifier [21]). Each of these tools relies primar-
ily on the basic assumption that residue functionality dictates sequence conservation,
Table 1 Summary of genetic variations in genome sequences of 12 individuals
Subject
ID
Eth, sex Total variants Coding variants Homozygous nsSNPs
(>q20) (Based on gencode v7) (Based on dbSNP build 137)







genesS MS NS Splice Indels Indels Indels SVs
overlap FS NFS overlap overlap
1 Afr, F 4513763 733596 4251 14793 14039 72 98 381 342 137 37 88 77 2 2
2 Afr, F 4472988 754399 4545 14500 13712 66 106 393 335 147 55 71 63 3 3
3 Afr, F 4287739 722922 4447 13755 13166 84 79 374 301 120 43 77 71 3 2
4 Afr, F 4443799 746111 4368 14488 13874 73 104 366 338 142 40 58 56 1 1
5 Cau, F 3734820 645032 3977 11929 11745 62 90 343 307 123 43 57 40 2 2
6 Cau, F 3691337 633475 4114 11757 11457 56 90 317 280 106 49 52 45 None None
7 Cau, F 3691270 632544 4033 11912 11488 65 71 279 304 116 37 50 44 4 4
8 Cau, F 3722234 641792 4197 11887 11434 64 76 303 299 125 41 55 42 None None
9 Cau, M 3647944 590064 3828 11619 11255 54 76 311 281 95 38 60 50 2 2
10 Cau, M 3643046 597363 4011 11814 11480 61 85 289 287 109 31 82 65 2 2
11 Cau, M 3650690 602744 3916 11560 11285 60 80 342 280 112 32 72 65 5 5
12 Cau, M 3701558 639005 4739 11842 11708 60 81 334 290 118 37 75 64 5 5
#Total = 797 #Unique = 575 #Total = 29 #Unique = 25
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programs were re-scaled to [0, 1] in which a score closer to 1 represents a stronger
(deleterious) effect of a nsSNP [10]. A MutationAssessor score of > 3.5 designates high
functional impact [19], hence, “deleterious”. The six prediction programs were used to
construct the classification scheme of nsSNPs presented in Table 2. Putative deleterious
nsSNPs were identified as nsSNPs reported as “deleterious” by at least three out of six
prediction programs.
In addition to the deleterious predictions, protein regions under evolutionary constraint
were detected using three evolutionary conservation-based indicators: GERP++ [22], phyloP
[23], and SiPhy [24]. We also used Grantham scores [25] to reflect the degree of physico-
chemical differences between pairs of amino acids. These four indicators were included in
the analysis for comparison purposes but were not utilized for nsSNP categorization.
Other popular variant annotation tools might also be useful but were considered to
be redundant with respect to our purposes. For example, ANNOVAR [26] has the ability
to perform variant annotation (intronic, intergenic, untranslated region, exonic: non-
synonymous, synonymous, etc.), but this information was already available from the
VAT output. At the time of our analysis, ANNOVAR provided dbSNP build 135 mapping,
not the dbSNP build 137 [11] used in our analysis pipeline. Note that gene definitions
from ANNOVAR refer to the nucleotide reference sequence where a SNP is located;
the format is not directly applicable for working with records from the two selected
SNP databases (MSV3d [14] and SwissVar [15]), in which UniProt accessions were
used to identify gene products. Similar to ANNOVAR, SnpEff [27] is another popular
program that can assign structural annotations of variants. This function would be
valuable when one wants to analyze different types of genetic variations within a genome.
Because we only focused on analysis of mis-sense mutations, the annotation feature of
SnpEff was deemed unnecessary.Supervised and automated structure-based predictions of variant function
High quality protein 3D structures are essential to identify functional impacts of nsSNPs.
Due to the limited availability of experimentally-determined human protein structures
[28], an assortment of 3D structure sources was used to manually evaluate the effects of
single point mutations found in specific proteins (Additional file 2: Table S1). Crystal
structures were retrieved from the RCSB Protein Data Bank (PDB) [29]. Homology
models were retrieved from Protein Model Portal (PMP) [30] repository, or were built
manually by joining multiple structures into a single model of a protein. Steric conflicts
found within homology models were resolved by energy minimization with explicit solvent
using YASARA force field [31]. Structural validation of homology models was evaluated by
using two independent scores: QMEAN6 [32] and ModFOLD4 [33]. All 3D structures
were visualized and rendered using Chimera [34].
The analysis began with a visualization of wild type proteins in the context of bound
ligands. Additional variants that are known to be associated with diseases, or affect
protein functionality and/or stability were also identified for each protein structure.
Next, we used SDM [35] to compare the protein stability changes upon amino acid
mutations with the default modeling of a mutant structure using Andante [36]. A
mutation is classified as affecting protein function (stabilizing or destabilizing) using
Table 2 AACDS classification of homozygous nsSNPs in 12 genomes









1 2 3 4 5 6 7 8 9 10 11 12
Afr, F Afr, F Afr, F Afr, F Cau, F Cau, F Cau, F Cau, F Cau, M Cau, M Cau, M Cau, M
Category 1 X 1 None None None 1 None None 1 1 None 1 None 5
2A X 8 7 6 5 6 5 11 7 12 7 10 9 93
2B X X 1 None None None 2 2 4 1 2 None 2 None 14
3A X 9 24 17 7 6 10 9 10 5 13 16 10 136
3B X X 1 5 None none 1 1 3 4 2 2 None 2 21
4 X 5 5 8 6 None 5 3 7 4 6 5 4 58
5 X X 14 21 20 10 8 12 9 11 13 18 20 14 170
6 68 40 49 42 46 32 33 33 40 56 45 55 539
Total #unique nsSNPs 88 71 77 58 57 52 50 55 60 82 72 75 797
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on protein stability in a high throughput fashion, we obtained the tertiary classification of
protein stability changes (increase, decrease, neutral) caused by a SNP from I-Mutant 2.0
[37], available from MSV3d [14]. The predictions are based on the protein (or homolog)
structure or solely on the protein sequence when the structure was unavailable.
In order to expand the structure-based predictions to a larger dataset without the
requirements of manual inspection or in-depth literature searches, we applied a combin-
ation of database searches and computational predictions to a larger set of proteins. In
addition to the 6 protein structures described in the main text, we identified an additional
25 protein coordinates from PDB [29] (Additional file 2: Table S2). We assessed these
25 wild type proteins in 4 areas of structural analysis: protein stability, ligand binding
capability, protein dynamics, and protein-protein interactions. For protein stability,
we used the aforementioned approach along with predictions of amino acids with
specialized roles regarding protein stability, namely long-range stabilization center
(SC) residues and stabilizing residues (SRs). These residues were inferred from the
SCide [38,39] and SRide webservers [40], respectively. Ligand binding residues for
each protein were retrieved from PDBe (www.ebi.ac.uk/pdbe/) or were predicted
using 3DLigandSite [41]. Amino acid residues that are located in or near predicted
binding pockets are likely to alter the binding capability for ligand(s). As disease-causing
mutations that do not occur in binding sites or buried sites are predominantly found on
protein interfaces [42], we used the PatchFinder program [43,44] to computationally pre-
dict the most significant cluster of conserved residues on a protein’s surface that may indi-
cate possible functional sites of the protein; i.e., sites of protein-protein interactions.
Changes in protein dynamics were evaluated by the crystallographic B-factor of Cα atoms.
In addition, we also used PredyFlexy [45] and FlexPred [46,47] to predict the dynamic
class of an amino acid residue (rigid, intermediate, flexible), and to estimate whether each
residue is likely to induce conformational switches within the protein.Assessment of functional enrichment
The g:Profiler web server [48] was used to detect enrichment of gene functions for
genes whose nsSNP are homozygous. Functional profiling and statistical enrichment
analysis were performed with two distinct methods. First, we compared the annotations
of multiple gene lists, where each list represents the genes with known homozygous
variants found in an individual, using G:Cocoa (n = 40–77 genes per genome). Then, we
analyzed a gene list for each individual using G:GOSt. The second analysis was performed
in two-steps: with and without genes harboring private variants. Enriched functions, such
as common gene ontology, biological pathways, shared transcription factor or miRNA
binding sites, were reported using the default g:SCS method for significance threshold
determination. It is worth mentioning that significant enrichment of protein-protein
interactions, derived from the BioGRID database [49], does not imply that all genes with
significant enrichment p-value are interacting with each other, but simply indicates which
query genes are present in the entire BioGRID dataset. The actual number of interactions
and associated genes can be visualized from the network output. The enriched annotations
and their gene members were confirmed by literature searches. Furthermore, the SNPshot
text-mining tool for PubMed abstracts was used to explore if any of the private
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drug or gene-disease associations [50].Results and discussion
Sequence-based variant description in 12 genomes
A total of 797 known homozygous non-synonymous substitutions was observed in
575 different genes (Table 1). The genomes of the four African individuals harbor on
average 73 homozygous nsSNPs (range 58–88), while the eight Caucasian genomes
have an average of 63 homozygous nsSNPs (range 50–82). The slight excess in African
Americans is not statistically significant (p = 0.18, 2-tailed t-test). 456 of the genes (79%)
have a single homozygous variant in the 12 genomes, but two genes (HLA-DRB5 and
ANKRD20A4) have more than 10, detected in at least 6 individuals.
The vast majority of all of the variants have been observed previously in the 1000Ge-
nomes project, with just 29 private homozygous nsSNPs observed in 25 different genes,
with a range of 0 to 5 per genome. Private variants were found in 10 out of 12 genomes
of CHDWB dataset and are listed in Additional file 2: Table S3. Most are predicted to
be neutral, though they affect nucleotides with a range of conservation levels. Almost
one-third of the 25 genes have no defined functions, and only a minor proportion of
the genes have been previously associated with a disease or trait.
Among the 575 genes whose nsSNPs are homozygous and present in dbSNP build
137, the fractions with known functions, putative functions, and unknown functions
are ~47, 20, and 33%, respectively (Table 3). Almost 10% of the homozygous nsSNPs
are found in four highly represented protein groups: transcriptional regulators, keratin-
associated proteins, odorant receptors, and zinc finger-containing proteins.
Six programs were used to predict deleterious variants, and three to indicate the level
of sequence conservation at the polymorphic site. The results are summarized in Figure 2,
which shows the cumulative number of predicted deleterious (blue) or highly conserved
(red) scores for each of the 797 variants. Although 58% of all homozygous mis-sense
variants in the 12 genomes alter conserved sites in all three assessments, almost 40%
of these (183/463) are predicted to be functionally neutral by all six programs. 45% of
the homozygous rare variants are predicted deleterious by at least one program, and
11% (88 variants) by three or more programs.
Differences among the deleteriousness prediction algorithms are underscored by the
cumulative score distribution plots in Figure 3. The solid lines in the top half of eachTable 3 Functional annotation of all homozygous nsSNP
Gene groups Genes nsSNPs Most common proteins
# % # % (#proteins, #nsSNPs)
Genes with known functions 268 47% 340 43% Transcriptional regulator proteins
(15 proteins, 17 nsSNPs), Keratin-associated
proteins (6 proteins, 9 nsSNPs)
Genes with putative functions 118 20% 167 21% Potential odorant receptors (21 proteins, 27 nsSNPs),
Zinc finger-containing proteins, potentially for
transcriptional regulations (16 proteins, 22 nsSNPs)
Genes with unknown functions 189 33% 290 36% -
Total 575 100% 797 100%
Figure 2 Number of deleterious and conserved site predictions. Data labels indicate the numbers of
homozygous nsSNPs predicted to be damaging or conserved by n programs (n = 0-6 for deleterious
predictions, and n = 0-3 for conservation predictions).
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503 homozygous rare variants in the Caucasians (blue). The two curves are not significantly
different, and predict that as many as 28% of variants are deleterious (MutationTaster) or
as few as 2% (MutationAssessor), with the two most commonly used algorithms, SIFT
and PolyPhen2, giving intermediate estimates of 80% neutral. The lower curves show
cumulative distributions for a set of 24703 disease-promoting non-synonymous variants
in 1789 proteins compiled from the MSV3d [14] and SwissVar [15] databases (red dashed
curve), as well as from subsets of these disease variants found only in the 23 genes (348
SNPs) harboring homozygous nsSNPs in the four African Americans, or 44 genes (547
SNPs) in the eight Caucasians in our sample (black and blue-dashed curves respectively).
All six programs show an elevated tendency to predict known disease-associated variants
in the genes harboring homozygous variants in the African Americans as neutral.Figure 3 Cumulative distribution plots for the six deleterious prediction scores. The X-axis represents
the prediction scores, ordered by the deleteriousness. The lowest and the highest scores for each prediction
algorithm indicate the neutral and damaging nsSNP, respectively. For each prediction program, the score
threshold for defining damaging SNPs is indicated by a vertical dashed green line (threshold for LRT is at
0.999). Five sets of SNP data are shown in each plot. Black solid lines: data from homozygous nsSNPs of four
African individuals; blue solid lines: data from homozygous nsSNPs of eight Caucasian individuals; red dashed
lines: data from all disease-causing nsSNPs (n = 24703 nsSNPs in 1789 proteins); black dashed lines: data from
disease-causing nsSNPs found in homozygous nsSNP-containing genes of the four African individuals (n = 348
nsSNPs in 23 genes); blue dashed lines: data from disease-causing nsSNPs found in homozygous nsSNP-
containing genes of the eight Caucasian individuals (n = 547 nsSNPs in 44 genes). All disease-causing nsSNPs
were retrieved from MSV3D [14] and SwissVar [15].
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SIFT. A similar observation of differences among Asians, Caucasians and Africans in
the fraction of damaging SNPs predicted deleterious was made by [51].
The notable differences in deleterious predictions given a set of disease-promoting
variants found in African American and Caucasian samples (Figure 3, lower curves)
suggest these prediction algorithms may have population-specific effects. To further
investigate that this observation is not an artifact of the small samples, we plotted
similar curves for a set of 1789 genes harboring disease SNPs (total 24703 SNPs). The
genes were classified into four groups depending upon population bias of their SNPs,
using %MAF difference cutoff of ± 5% between European American (EA) and African
American (AA) populations. The four gene groups are: EA bias, AA bias, EA&AA
bias, and no bias. Unlike Figure 3 where homozygous variants in the African
Americans were consistently predicted to be more neutral, the larger-sample plots
(Additional file 3: Figure S2) illustrate a small difference in the cumulative scores
of population specific-disease SNPs, with the exception of a noticeable prediction bias of
MutationTaster. The results highlight the need for development of mutation assessment
pipelines that go beyond these algorithms, particularly when evaluating homozygous
nsSNPs of non-Caucasian genomes.Association-adjusted consensus deleterious scheme (AACDS) for variant classification
Consequently, we developed a ranking system that classifies homozygous nsSNPs
into eight categories according to the overlap of (i) consensus deleterious predic-
tion, (ii) documentation that the SNP causes a disease, and evidence that the SNP is in a
gene that has been associated with (iii) a disease or (iv) a quantitative trait (Figure 1).
Category 1 contains documented disease-causing nsSNPs. Categories 2A and 3A repre-
sent nsSNPs in genes that have known associations with diseases (2A) or traits (3A), and
these are sub-divided into categories 2B and 3B if they are also predicted to be deleterious
by three or more programs. Category 4 comprises nsSNPs that are predicted to be dam-
aging but lie in genes that have no clinical associations. Conversely, Category 5 nsSNPs
are located in genes that have disease or trait associations, but variants are predicted to be
neutral. Category 6 represents neutral nsSNPs, whose genes have no clinical relations.
Table 2 lists the number of variants in each category from each individual’s genome.
The list of disease-promoting nsSNPs was retrieved from MSV3d [14] and SwissVar
[15] and is based on manual curation of evidence that the variant is causal, or probably
causal, in disease. Most are relatively rare (MAF < 5%) presumed highly penetrant
mutations, but an unknown fraction may be false positives. Among the 575 genes in
our dataset, 93 harbor disease causal variants (n = 787 nsSNPs). The 797 homozygous
nsSNPs in our dataset include 4 category 1 “disease-causing” mutations (1 SNP is
present in two individuals) and another 6 listed as probably pathogenic (Table 4).
Another 143 are classified as having unknown effects, leaving 644 polymorphisms
presumed not to cause disease in a highly penetrant manner. The 10 probably or
known pathogenic mis-sense variants were predicted to be deleterious by 0 to 5 programs
(Table 4).
Among the 93 disease-associated genes with homozygous nsSNPs in our CHDWB
genomes, 18 have homozygous variants present in more than one individual, and these
Table 4 List of all four known disease-causal variants and six probable pathogenic variants
SNP type Gene Position, base
change (AA change)
rsID (%MAF EA/AA/All) Disease [prediction counts] Grantham score Protein
stability change
Site annotations
Disease-causal ATP6V0A4 7:138417791 rs3807153* (4.8/18.5/9.4) Distal renal tubular acidosis (dRTA) with preserved hearing 81 Neutral TRANSMEM
A–>G (M580T) [Del count: 2; Con count: 3]
MTMR2 11:95569448 rs558018 (0.02/3.9/1.3) Charcot-Marie-Tooth disease type 4B1 (CMT4B1) 46 Decrease DOMAIN
T–>C (N545S) [Del count: 2; Con count: 3]
APOE 19:45412079 rs7412 (5.6/8.7/6.6) Lipoprotein glomerulopathy (LPG) 180 Decrease REPEAT
C–>T (R176C) [Del count: 5; Con count: 3]
BMP15 X:50658966 rs104894767 (1.4/0.3/1.0) Premature ovarian failure type 4 (POF4) 58 Neutral PROPEP
G–>A (A180T) [Del count: 0; Con count: 1]
Probable pathogenic FRZB 2:183699584 rs7775 (8.8/28.4/15.4) Osteoarthritis type 1 (OS1) 125 Neutral -
G–>C (R324G) [Del count: 1; Con count: 3]
HABP2 10:115348046 rs7080536 (3.9/0.7/2.8) [Del count: 5; Con count: 3] 98 Decrease DOMAIN
G–>A (G534E)
HNF1A 12:121416650 rs1169288 (33.5/12.1/26.2) Insulin-dependent diabetes mellitus type 20 (IDDM20) 5 Neutral REGION
(Dimerization)
A–>C (I27L) [Del count: 1; Con count: 3]
XYLT1 16:17564311 rs61758388 (-/-/1.7) [Del count: 0; Con count: 3] 99 Neutral TOPO_DOM
C–>A (A115S)
CYP2A6 19:41354533 rs1801272 (2.5/0.5/1.8) [Del count: 1; Con count: 3] 99 Decrease -
A–>T (L160H)
ADA 20:43255220 rs11555566 (6.3/6.8/6.5) Severe combined immunodeficiency autosomal
recessive T-cell-negative/B-cell- negative/NK-cell-negative
due to adenosine deaminase deficiency (ADASCID)
26 Decrease -
T–>C (K80R)
[Del count: 1; Con count: 3]
*The first SNP (rs3807153) was observed in two individuals.
The minor allele frequency (MAF) in percent listed in the order of European American (EA), African American (AA), and all populations (All), delimited by “/”. Prediction counts indicate the number of deleterious predictions (Del
count) and conservation predictions (Con count) by six and three programs, respectively. Grantham score determines the similarity in amino acid changes: small (score < 60), intermediate (score 60–99), and large (score≥ 100).
Tertiary classification (increase, decrease, neutral) for protein stability change caused by a SNP was obtained from I-Mutant 2.0 [37], available from MSV3d [14]. Site annotations list any structurally/functionally important sites
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the MYH6 myosin heavy chain, is predicted to be deleterious. Since it is also associated
with resting heart rate, it is classified in both categories 2B and 3B. Data for the variant
categorization in these 18 disease-associated genes is summarized in Additional file 2:
Table S4. Similarly, we also observed 101 genes with trait associations, including 126
SNPs. Since there are a total of 14 and 21 variants in categories 2B and 3B respectively,
most of these cases are restricted to a single individual in the sample of 12. Details
for these predicted deleterious variants are listed in Additional file 2: Tables S5, S6,
respectively. On average, each individual carries 3.33 category 1, 2B or 3B homozygous
variants (range 0 to 7), and although the two individuals with no variants of this type are
both African Americans, there is no significant difference in prevalence relative to the
Caucasians (p = 0.21, 2-tailed t-test). All of the remaining predicted deleterious variant
that do not have disease or trait associations (namely, category 4) are listed in Additional
file 2: Table S7.
The set of 35 disease- or trait-associated SNPs that are also predicted to be deleterious
is seven times larger than the set of 5 category 1 “known to be deleterious” mutations.
They represent 15% of the 93 disease-associated and 136 trait-associated category 2A and
3A SNPs. Additional file 4: Figure S3 compares the allele frequency distributions of the
2B/3B SNPs relative to all 2A/3A SNPs and shows a tendency to reduced allele frequency,
also consistent with them having deleterious effects on fitness. Another 170 homozygous
nsSNPs lie in genes that have been associated with diseases or traits but are not predicted
to be deleterious (category 5). Their frequency distribution is approximately equivalent to
those of the category 2A and 3A SNPs. The vast majority (539) of the 797 SNPs we have
considered are in category 6 and represent the subsets that are least likely to be damaging.
A limitation of our analysis is the uncertainty in the accuracy of phenotypic annotations
of SNPs, as well as the variable confidence level in annotations of causal SNPs. We
obtained the list of disease-promoting nsSNPs from MSV3d [14] and SwissVar [15].
Most of the variants were classified as either causal variants (to a specific disease), or as
polymorphisms. In MSV3d, many variants have ambiguous annotations, e.g., probable-
pathogenic, or unknown. In SwissVar, some proteins are noted to have associations with
diseases, but the list of variants is not provided.Supervised structure-based variant evaluation
Personal genome studies indicate that each healthy individual carries a large number of
rare homozygous genetic variants [52-55]. While these variants can be found in any
structural regions along the genome and can have diverse effects on biological function,
Cooper (2010) estimated that as many as 60% of known disease-causing mutations are
nsSNPs [2]. This viewpoint simply reflects the more obvious impact of nsSNPs on coding
regions than regulatory regions: the substitutions tend to alter the amino acid sequences
of the proteins. Amino acid changes are thought to have profound effects on the protein,
impacting their structure or function. Furthermore, it is believed that there exist some
structure-function relationships for each individual amino acid residue within a protein
chain, and the 3D structure is an ideal resource for investigating this information [56].
Therefore, many algorithms have been developed to assess the effects of amino acid
changes within the context of protein 3D structures. Numerous structural features have
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demonstrated that protein 3D structures add to prediction accuracy [58,59]. In addition,
in silico analysis of 3D structures can facilitate variant prioritization because it provides
systematic screening of nsSNP effects in the context of the protein structure and suggests
which mutations may critically alter the function of the protein.
Implementation of the AACDS classification scheme reduces the number of potentially
deleterious variants to a number per genome that can feasibly be evaluated manually
on a case-by-case basis. For this purpose, we have devised a further pipeline that involves
sequence annotations, extracting either X-ray crystal/NMR structures or homology
models from structure databases, and computing a series of predictions that capture
protein features. In this way, each of the up to 5 variants in categories 1, 2B or 3B
can be assessed in the context of the actual protein. While this approach requires that
an individual with experience in protein structures be engaged in the personal genome
evaluation, the potential gain in accuracy is likely to be meaningful.
Our preliminary analysis utilized sequence features for all amino acid residues in each
protein, obtained from UniProt features records [13]. The entries had been curated and
are predicted (and compatible with the protein function), experimentally proven, or
determined by resolution of the protein structure. The analysis was restricted to 62%
of the nsSNPs, since the remaining fractions do not currently have feature information.
Figure 4 illustrates that although the annotated 494 nsSNPs are found in various sequence
regions, they are predominately present in transmembrane and protein domains. These
proportions are approximately equivalent to the proportions of each of the 9 types of
annotated protein region for all residues in the included proteins (Additional file 5:
Figure S4). Locations of homozygous variants relative to the length of each sequence
feature indicate the variants are located throughout the entire sequence length (Additional
file 6: Figure S5).
Subsequent detailed analyses involved manual inspection and evaluation of individual
proteins. The remainder of this section discusses detailed structural evaluations of two
known causative variants, two predicted deleterious variants in proteins that have been
associated with a disease or trait, and two predicted deleterious variants for which the
clinical associations are inconclusive. The first disease causing nsSNP is the well-
known Arginine to Cysteine substitution at residue 176 (residue 158 if omitting the sig-
nal peptide) that defines the APOE2 allele of Apolipoprotein 2 (SNP category 1/2B/3B).Figure 4 Distribution of homozygous nsSNPs by sequence type. Data labels indicate the number (and
percentage) of SNPs altering protein residues with each specified sequence feature. All sequence features
were obtained from the UniProt database [13].
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late-onset Alzheimer’s disease and coronary artery disease [60-62]. Homozygosity for
R176C is also associated with Type III hyperlipoproteinemia (HLPP3) in approximately
2% of cases (though 94% of HLPP3 cases have the genotype) [63]. Onset of the disorder
is usually only after menopause in women and rarely manifests before the third decade
in men. Several other rare variants in the gene have been annotated to disease, most of
which affect intra- and inter-helical salt bridges (Figure 5A). With the neutral cysteine
at position 176 in APOE2 protein, this pattern of salt bridge is eliminated. Al-
though Arg176 does not interact with the LDL receptor, the R176C substitution
has been shown to indirectly reduce the receptor-binding activity of APOE [64]. Sta-
bility prediction indicates this mutation has neutral effect to the protein stability
(ΔΔG = −0.46 kcal mol-1).
The second example of causative mutation is in Myotubularin-related protein 2
(MTMR2), a putative tyrosine kinase that is associated with Charcot-Marie-ToothFigure 5 Location of variants in six protein structures. A-B describe two causative variants, C-D demonstrate
two predicted deleterious variants, E-F illustrate two predicted deleterious variants whose clinical
associations are inconclusive. For all figures, the representations are as follows: ribbon for proteins, ball and stick
for ligands, mesh for ligand binding sites, and sphere for amino acid variants. Amino acid variants caused by
homozygous or heterozygous nsSNPs are indicated as (***) or (*), respectively. Additional variants that are
known to be associated with diseases (D), or affect protein functionality (F), and/or stability (S) are also
identified. A: Apolipoprotein E (PDB:2L7B). B: Myotubularin-related protein 2 (PDB:1LW3). C: Thrombospondin-1
(PDB:1UX6 and homology model). Residues 1–548 are missing from the structure, residues 549–829
(brown ribbons) are modeled from human THBS2 (PDB:1YO8), residues 848–1169 (white ribbons) are from
a crystal structure of THBS1 (PDB:1UX6). Coordination complexes of amino acid side chains and Ca2+ ions
(green spheres) as seen in the crystal structures are indicated with purple lines. The Ca2+ ions with
unidentified coordination complexes are derived from the superposition of Ca2+ ions in 1YO8 onto the
homology model. D: Acidic mammalian chitinase (PDB:3FY1). Three homozygous nsSNPs were also
identified from the same genome, but only two are present in the crystal structure. E: Myosin heavy chain
6 (αMyHC) modeled from Myosin heavy chain 7 (βMyHC) (PDB:4DB1). The C-terminal
(residues 778–1939) is missing from the template crystal structure. F: Pancreatic alpha-amylase (AMY2A)
(PDB:3OLE). The Pro145 is located at the end of the extended β-loop and is part of a binding site for α-D-glucose.
For clarity, only one α-D-glucose binding site is shown. Other variants known to affect the enzymatic
activities are located around the chloride ion (green sphere) in the central vicinity of the protein.
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substitution at the position 545 of the protein that has previously been reported as a
rare variant in patients with CMT disease [66]. This SNP is classified as category 1.
The minor allele frequency of this nsSNP is reported as 3.88% and 0.02% in African
Americans, and European Americans, respectively, so the penetrance is much reduced
in African Americans since disease prevalence of all forms of CMT is just one in 2500
[67]. The variant is situated in a conserved site, but only two algorithms predict it to be
deleterious. The crystal structure places Asn545 in a protein domain, but it is not in
close proximity with two other causative variants or part of a binding site. This muta-
tion is also predicted to be neutral (ΔΔG= 0.36 kcal mol-1) (Figure 5B).
One predicted damaging nsSNP was found in Thrombospondin 1 (THBS1), a glyco-
protein that stabilizes fibrinogen platelet cross-bridges [68]. The homology model indi-
cates the substitution of a Serine for Asparagine at residue 700 of THBS1 occurs at a
critical position in one of the calcium-binding domains (green spheres project coordin-
ation of CA2+ ions) (Figure 5C). This Asn700Ser substitution in THBS1 (SNP category
4) has a prevalence of 8-10% in Europeans [69] and is associated with the occurrence
of premature (age < 45) coronary heart disease in both homozygous and heterozygous
individuals [68]. However, a study of Asn702Ser in THBS2 (homologous to 700 in
THBS1) demonstrated that this variant does not alter calcium-binding capability. In-
stead, it induces a local conformational change leading to destabilization of surround-
ing structures [69], consistent with the computational prediction that the variant has a
destabilizing ΔΔG of 0.58 kcal mol-1.
The second example of a predicted deleterious nsSNP is a mis-sense substitution in
Acidic mammalian chitinase (CHIA), an enzyme that stimulates chemokine production
by pulmonary epithelial cells. Arg35Trp (SNP category 4) is located in a buried site,
where it causes changes in residue side chain volume, charge, polarity, and hydrophobi-
city (Figure 5D). The substitution was predicted to disrupt the hydrophobicity of the
protein and increase solvent accessibility of the residue [14]. The individual who is
homozygous for this variant also carries three heterozygous nsSNPs (N278D, I339V,
and V432G). The first two of these replacements are parts of disulfide bonds, while the
third substitution resides in the chitin-binding domain. Interestingly, the Arg35Trp mu-
tation is predicted to stabilize the protein (ΔΔG = −1.19 kcal mol-1), a finding that may
appear counter-intuitive. However, it is suggested that protein flexibility is crucial for
enzyme catalysis [35]. The increase in protein stability and the dramatic change in
physicochemical properties caused by this homozygous nsSNP, along with the disulfide
bond reduction from heterozygous variants, strongly suggest the possibility for protein
malfunction in this individual. As far as we are aware, he does not have asthma or an
aberrant T-helper mediated inflammatory response, but deeper clinical investigation
may be warranted.
The last two examples highlight cases where the variant is predicted deleterious but
its clinical associations are inconclusive. The first example is a Glycine to Arginine sub-
stitution at residue 56 of Myosin heavy chain alpha (MYH6) (SNP category 2B/3B). As
mentioned earlier, this is the only predicted deleterious variant among a set of 18
disease-associated genes with variants present in more than one individual (Additional
file 2: Table S4). SNP databases indicate six well known causative variants in this gene
that lead to familial hypertrophic cardiomyopathy and atrial septal defect. Although
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viduals but it does not segregate perfectly with the disease in families of probands
[70,71]. With regard to the homology model (Figure 5E), many of the known variants
associating with heart disease are located in the coiled-coil regions of this protein
(missing from the crystal structure) and are not part of the ATPase catalytic site or
actin binding site. Nonetheless, the G56R found in one of the CHDWB participants is
particularly interesting, since the mutation occurs in a myosin head-like domain, a
key component for muscle contraction, and with a large degree of amino acid change
(Grantham score = 125). Stability prediction also suggests this variant destabilizes the
protein (ΔΔG = 1.10 kcal mol-1).
The second example of a variant with uncertain functional effect is taken from a set
of 143 SNPs (18% of CHDWB dataset) that do not currently have phenotypic annota-
tions. Among these, 117 SNPs have neither disease nor trait association at the gene
level. Form 143 SNPs, we identified 15 variants predicted to be damaging, of which 8
are located in genes with no clinical associations. Our example is a Proline to Serine
substitution at residue 145 of Pancreatic alpha-amylase (AMY2A) (SNP category 4). In
addition to one calcium ion and one chloride ion per subunit, the protein is able to
bind to several ligands throughout the structure. Mutagenesis studies identified several
amino acid residues that are essential for the protein’s catalytic activity and affinity to
calcium and chloride ions, but the impact of Pro145Ser has not been established
[72,73]. Despite the limited information of the variant, crystal structure indicates
Pro145 is part of one, among many, binding sites for alpha-D-glucose (Figure 5F). In
general, amino acids with similar physicochemical properties may substitute each other
while maintaining the protein’s functionality. One study demonstrates some uncom-
monly predominant inter-species amino acid variations, such as serine-proline pairs or
glutamic acid-alanine pairs [74]. The notable feature corresponds with the proline to
serine substitution caused by this SNP. It is well known that the proline residue is ster-
ically restricted and that it tends to disrupt regular secondary structural elements. Most
proline residues are found in very tight turns or on protein surface [75]. The unusual
occurrence of Pro145, especially in the extended β-loop indicates that this residue is es-
sential for proper protein folding. Further investigation revealed that this residue is in
the cis isomer, a very rare phenomenon since proline residues are exclusively synthe-
sized as the trans isomer. In fact, AMY2A contains two cis-proline residues (Pro69 and
Pro145); both are located in the loop regions. It had been suggested that the two resi-
dues help accommodate a sharp turn of the β-loop [76]. Substitution of proline to
serine is predicted to be highly stabilizing for residue 145 (ΔΔG = −2.77 kcal mol-1), but
highly destabilizing for residue 69 (ΔΔG= 5.23 kcal mol-1). In any case, strong stability
changes are suggested to cause protein malfunction and may lead to disease(s) [35].Automated structure-based variant evaluation
To facilitate high throughput evaluation of protein structures, we devised a structural ana-
lysis pipeline that assesses the functionality of protein residues using data directly obtained
from the atomic coordinates or from computational predictions. Using this approach, a list
of potentially deleterious variants from a structural perspective can be generated rapidly,
providing a way to integrate structural analysis into the variant categorization scheme.
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ity, and potential to disrupt protein-protein or protein-small molecule interactions.
Many mutations disrupt these structural features and as a result, lead to altered protein
functions or diseases. Our assumption is that the analysis may be able to identify some
variants with strong effects. The results are summarized in Additional file 2: Table S8,
which indicates that predicted deleterious variants show a wide variety of residue fea-
tures. In general, SNPs that do not cause stability change (ΔΔG < ± 0.5 kcal mol-1) tend
to be non-deleterious, but not vice versa. Four amino acid residues have B-factors of
Cα atoms larger than 60 Å2, a characteristic which may indicate that the atom is disor-
dered due to dynamic motion, or may be an artifact of crystal imperfection. However,
three out of these four amino acids are predicted to be at rigid sites and do not induce
conformational switches. Another three residues are predicted to lie within a cluster of
conserved residues on a protein surface, but none is categorized as damaging variants.
Lastly, we found only one amino acid mutation that is located within the binding site,
but the variant is in categories 2A and so not predicted to be damaging.
Imposing the constraint that the 3D structures must be of high quality, our initial
analysis was restricted to only 24 experimentally-determined structures and 1 high
quality theoretical model. Their sequence coverage ranges from 23–100% (average
69%) (Additional file 2: Table S2). However, the implementation can be further ap-
plied to any available structures. For example, using the automated Phyre2 homology
modeling server with single/multiple template methodology [77], we were able to
model an additional 77 full length proteins with high confidence. Each full length pro-
tein model has a percentage of residues modeled at >90% confidence in the range of
59-99% (average 86%). For larger proteins (>1300 amino acids), we truncated them
into smaller domain(s) and our modeling attempt returned 10 models with confidence
between 96-100%.Enrichment for mutations disrupting protein interactions
As a parallel approach to evaluating the deleterious potential in homozygous protein
substitutions, we used g:Cocoa [48] to evaluate whether there is an enrichment for
proteins that have similar functions. The analysis revealed four significant gene anno-
tations that include a significant number of the queried genes from more than one in-
dividual. These four terms are: X-linked recessive inheritance, epithelial cell signaling
in H.pylori infection, microRNA miR-708 binding sites, and Rho GTPase signaling
pathway (Additional file 7: Figure S6).
Although 96 homozygous nsSNPs were identified on the X chromosome, only 1
nsSNP has been documented as a causal variant (X:50658966G → A) (Table 4). Genes
involved in X-linked recessive inheritance from the 12 genome data were identified in
one African female and four Caucasian males (Additional file 2: Table S9). We identi-
fied only two predicted damaging SNPs. One was found in TBX22 that is associated
with X-linked cleft palate. The other is located in SYTL5, a trait gene associated with
erectile dysfunction and prostate cancer treatment. The remaining X chromosome vari-
ants are predicted as neutral. Two male individuals have the same mutation in the F9
gene, for which reduced function can result in hemophilia B (HEMB). Unlike
hemophilia A, symptoms of HEMB are usually milder or can be asymptomatic. Three
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can cause nystagmus congenital X- linked type 1 (NYS1), a condition that appears at
birth and up to three months old. The indications are spontaneous and involuntary
ocular oscillations. Given that most X-chromosome variants are predicted neutral and
there is no indication that either of these individuals have these conditions, it is un-
likely that the associated disease or trait will develop.
Finally, we used BioGRID [49] to evaluate enrichment for proteins that form physical
interaction networks, and found that one of the 12 individual’s genomes has 7 muta-
tions potentially involved in an unusually high number of contacts (Additional file 8:
Figure S7). Three of these proteins (FHL2, STK17A, and DSP) are linked together by
other interacting partners. The FHL2 gene encodes a four and a half LIM domain pro-
tein that acts as a molecular transmitter between signaling pathways and transcriptional
regulation. The wild type amino acid affected by the homozygous mis-sense variant of
the FHL2 gene is evolutionarily conserved, but the Arg177Gln substitution is only pre-
dicted to be deleterious by one program. This variant is not predicted to affect protein
stability and the protein is not associated with a disease or trait. However, we mention
it as an example of how this approach may highlight networks of proteins, where subtle
modification of multiple partners may result in cumulative disruption that would lead
to disease under a multiplicative burden of rare variants model.Conclusions
Intensive resource requirements and the associated costs make it infeasible to experi-
mentally verify the effect of every genetic variation. At this stage of human genome
study, in silico predictions play an important role in identifying putative functional vari-
ants. While a sequence-based approach is the current standard practice for assessing
SNP effects, there are still some concerns that sequence conservation alone is not a re-
liable predictor of deleteriousness. In this study, we propose the AACDS classification
scheme using variant annotation and sequence-based predictions. We used AACDS to
classify homozygous nsSNPs found in the genomes of twelve healthy individuals into
eight categories according to the consensus sequence-based deleterious prediction,
types of mutation (disease-associated vs. neutral), and information on disease- or
trait-associations with the gene. The classification scheme provides a comprehensive
framework for prioritizing a list of SNPs suitable for detailed evaluation, in this study
reducing the evaluation space from 826 to 98 variants (in categories 1, 2B, 3B, and 4).
An online tool for computing the AACDS scores for any variant is provided at
http://aacds.cig.biology.gatech.edu/?q=tools.
Several previous studies have shown that structural information plays an important
role in understanding the relationship between genetic variation and the structure and
function of the protein. The addition of 3D structural analysis following AACDS classi-
fication demonstrates how structure data can complement sequence-based prediction,
and highlights how functional interpretation can in some cases be inferred exclusively
from 3D structures. By using a combination of solved structures or high quality hom-
ology models for all human proteins, we demonstrate that up to 117 of the 575 proteins
bearing homozygous mutations in our CHDWB dataset are available for detailed SNP
evaluation, providing detailed analysis of the 150 prioritized variants.
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Additional file 1: Figure S1. AACDS summary report. The report is provided to the user with the AACDS
category of the variant and its relevant information, along with additional variant data.
Additional file 2: Table S1. List of protein structures used in supervised structural analysis. Table S2. List of
protein structures used in automated structural analysis. Table S3. List of all private variants in the 12 genomes.
Table S4. List of all Categories 2A/2B variants affecting the same gene in more than one individual. Table S5.
List of all Category 2B variants. Table S6. List of all Category 3B variants. Table S7. List of all Category 4 Variants.
Table S8. Summary of automated structural analysis. Table S9. List of X-linked recessive mutations.
Additional file 3: Figure S2. Cumulative distribution plots for the six deleterious prediction scores. The X-axis
represents the prediction scores, ordered by deleteriousness such that low and high scores for each prediction
algorithm indicate neutral and damaging nsSNPs, respectively. For each prediction program, the score threshold
for defining damaging SNPs is indicated by a vertical green line (threshold for LRT is at 0.999). The genes were
classified into four groups depending upon population prevalence of their SNPs, using the difference in minor
allele frequencies (MAFs) (cutoff of ± 5%) between European American (EA) and African American (AA) populations.
The four gene groups are EA bias, AA bias, EA&AA bias, and no bias. For each plot, the dashed lines illustrate the
cumulative distribution of deleterious prediction scores for disease-causing SNPs located in each gene group. The
numbers of genes and SNPs are as follows: EA bias (222 genes, 3409 SNPs), AA bias (368 genes, 4825 SNPS), EA&AA
bias (234 genes, 4225 SNPs), and no bias (965 genes, 12214 SNPs). All disease-causing nsSNPs were retrieved from
MSV3D [14] and SwissVar [15]. Population-specific minor allele frequencies for the variants were derived from NHLBI
GO Exome Sequencing Project (ESP6500) (June 2012 release) [12].
Additional file 4: Figure S3. Allele frequency distributions by AACDS score. The three columns indicate the
minor allele frequency (MAF) in percent, listed in the order of European American (EA), African American (AA) and
all populations (All). Only SNPs with available allele frequency data are represented here and the numbers in each
group are 221, 33 and 165, respectively.
Additional file 5: Figure S4. Proportions of the 9 types of annotated protein regions found in all residues in the
analyzed proteins vs. in SNP residues. Data were compiled from a set of 520 proteins whose sequence features are
available from UniProt database [13].
Additional file 6: Figure S5. Location of SNPs within proteins according to sequence feature type. A relative
location near zero indicates the SNP is located near the N-terminus of that sequence feature. For clarity, a few fea-
tures were excluded due to small sample sizes.
Additional file 7: Figure S6. Comparison of gene functional enrichment in the 12 genomes. The analysis was
performed with g:Cocoa [47]. Each cell in the left most column indicates the number of queried genes from each
individual that are associated with each annotation term. The highlighted cells indicate significant enrichment. The
enrichment p-values are determined by the default multiple testing correction procedure g:SCS. The column “Term
genes” indicate the total number of genes associated to each functional term. Abbreviations: bi: BioGRID protein-
protein interaction network; co: CORUM protein complexes; hp: human disease genes from Human Phenotype
Ontology; ke/re: KEGG/REACTOME pathway; mi: MicroCosm microRNA sites.
Additional file 8: Figure S7. BioGRID network for protein interactions in one person’s genome. The red nodes
highlight a subset of the query that is connected by an edge in the network. The black nodes are the immediate
neighbors of the red nodes. The one private homozygous nsSNP from this individual is found in the STK17A gene.
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